



September 4, 2008

## **Astellas and APP Pharmaceuticals Announce Transfer of the Grand Island Plant**

Tokyo, Japan and Schaumburg, IL - September 4, 2008 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and APP Pharmaceuticals, Inc. (“APP”; Nasdaq: APPX; headquarters: Schaumburg; President and CEO: Thomas H. Silberg) today announced the sale and transfer of the Grand Island, N.Y. plant owned by Astellas’s wholly owned subsidiary, Astellas Pharma Manufacturing, Inc., to APP on September 3, 2008.

“Astellas has previously declared in its mid-term 5-year management plan ending FY2010 (fiscal year ending March 2011) that the number of production sites will be reduced to around 10 by FY2010 to achieve an optimal production system. This transfer of the plant has been carried out as one of the important steps for Astellas’s mid-term 5-year management plan,” said Hitoshi Ohta, Astellas’s Senior Corporate Executive and Vice President, Technology.

Thomas H. Silberg, APP’s President and CEO, stated, “This acquisition adds needed manufacturing capacity, complements our existing operations in Grand Island and facilitates the continued growth of our business.”

The transfer of the plant was immediate upon execution of the agreement. To ensure no interruption in supply, Astellas has agreed to lease the plant from APP and will continue manufacturing Protopic<sup>®</sup> (tacrolimus ointment) for the treatment of atopic dermatitis at the Grand Island facility into the spring of 2009. After the termination of the lease, Protopic will be manufactured at Astellas’s Toyama plant located in Japan. In addition, APP has agreed to offer employment to a majority of the employees at the Grand Island plant.

The outline of the Grand Island plant is described below.

Owner Name:	Astellas Pharma Manufacturing, Inc.
Location:	Grand Island, N.Y.
Business Description:	Pharmaceutical manufacturing (drug production and packaging)
Employees:	Approximately 90 in the Grand Island plant (as of July 31, 2008)

### **About Astellas**

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas has approximately 13,700 employees worldwide. The organization is committed to becoming a global category leader by rapidly establishing a business model in Urology, Immunology and Inflammatory, Diabetes, CNS/Pain, Infectious diseases (virus) and Cancer. We have discovered an over-active bladder (OAB) medication, Vesicare<sup>®</sup> and an immunosuppressive agent, Prograf<sup>®</sup> (tacrolimus), which have enabled us to become an established leader in both Urology and Transplant. For more information on Astellas Pharma Inc., please visit our website at [www.astellas.com](http://www.astellas.com).

**About APP**

APP is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on oncology, anti-infective, anesthetic/analgesic and critical care markets. The company is one of the largest producers of injectables, with more than 100 generic products in more than 400 dosage formulations. APP, headquartered in Schaumburg, Illinois, has offices in Canada and manufacturing operations in Illinois, New York and Puerto Rico and is traded on the Nasdaq Global Market under the symbol APPX. For more information about APP and the products it provides, please visit [www.APPpharma.com](http://www.APPpharma.com).

#####

Astellas Contact:  
Corporate Communications  
Tel.: +81-3-3244-3201

APP Contact:  
Corporate Communications  
Tel: +310-405-7522